Gapping down
In reaction to disappointing earnings/guidance: EXTR -19.8%, MDCO -7.3%, ANGO -5.8%, CTXS -5.7%, TSRI -4.5%, DHRM -3.9%, FIS -3.6%, PSMT -2.8%, GPS -2%
Select China related names showing weakness (likely related to profit taking after recent run up) : YZC -3.8%, CHU -3.6%, PTR -2.5%, SNP -2.3%, CHL -2%, SHI -1.7%, LFC -1.6%
Other news: GALE -7.9% (disclosed it received a Warning Letter from the FDA relating to certain matters identified in previous Form 483 Notice), CMP -4.4% (reports that above average Q1 snow events in the company's core North American service area offset mild weather in December), AZN -3.2% (Briefing documents released ahead of Endocrinologic and Metabolic Drugs Advisory Committee meeting on AZN and Takeda (TKPYY)), AMRN -3.1% (filed for ~35.215 mln share ordinary share offering and for a ~352.15 mln Series A preference share offering by selling shareholders), QURE -2.9% (prices 3,000,000 ordinary shares at $29.50 per ordinary share), GBDC -2.6% (announced public offering of 3.5 mln shares of its common stock), RDC -1.5% (disclosed that the Rowan Reliance drillship experienced a loss of seal in the riser connection system)
Analyst comments: RESI -1% (downgraded to Mkt Perform from Outperform at Keefe Bruyette), LPX -1% (downgraded to Neutral from Buy at BofA/Merrill), SEE -0.9% (initiated with a Market Perform at BMO Capital), WLL -0.7% (downgraded to Hold from Buy at Canaccord Genuity)
In reaction to disappointing earnings/guidance: EXTR -19.8%, MDCO -7.3%, ANGO -5.8%, CTXS -5.7%, TSRI -4.5%, DHRM -3.9%, FIS -3.6%, PSMT -2.8%, GPS -2%
Select China related names showing weakness (likely related to profit taking after recent run up) : YZC -3.8%, CHU -3.6%, PTR -2.5%, SNP -2.3%, CHL -2%, SHI -1.7%, LFC -1.6%
Other news: GALE -7.9% (disclosed it received a Warning Letter from the FDA relating to certain matters identified in previous Form 483 Notice), CMP -4.4% (reports that above average Q1 snow events in the company's core North American service area offset mild weather in December), AZN -3.2% (Briefing documents released ahead of Endocrinologic and Metabolic Drugs Advisory Committee meeting on AZN and Takeda (TKPYY)), AMRN -3.1% (filed for ~35.215 mln share ordinary share offering and for a ~352.15 mln Series A preference share offering by selling shareholders), QURE -2.9% (prices 3,000,000 ordinary shares at $29.50 per ordinary share), GBDC -2.6% (announced public offering of 3.5 mln shares of its common stock), RDC -1.5% (disclosed that the Rowan Reliance drillship experienced a loss of seal in the riser connection system)
Analyst comments: RESI -1% (downgraded to Mkt Perform from Outperform at Keefe Bruyette), LPX -1% (downgraded to Neutral from Buy at BofA/Merrill), SEE -0.9% (initiated with a Market Perform at BMO Capital), WLL -0.7% (downgraded to Hold from Buy at Canaccord Genuity)